𝗪𝗵𝗮𝘁 𝗱𝗼𝗲𝘀 ´𝗖𝗗𝟴´ 𝗺𝗲𝗮𝗻? 
CD8 refers to a 𝘤𝘭𝘶𝘴𝘵𝘦𝘳 𝘰𝘧 𝘥𝘪𝘧𝘧𝘦𝘳𝘦𝘯𝘵𝘪𝘢𝘵𝘪𝘰𝘯 glycoprotein on cytotoxic T cells. It acts as a co-receptor with the T cell receptor (TCR), binding to MHC class I molecules and stabilizing recognition of antigenic peptides. CD8⁺ T cells are specialized in detecting intracellular infections and malignant transformations [1]. 

𝗠𝗼𝗱𝗲𝘀 𝗼𝗳 𝗞𝗶𝗹𝗹𝗶𝗻𝗴 
CD8⁺ cytotoxic T lymphocytes (CTLs) eliminate their targets through two primary mechanisms. First, 𝘷𝘪𝘢 𝘨𝘳𝘢𝘯𝘶𝘭𝘦 𝘦𝘹𝘰𝘤𝘺𝘵𝘰𝘴𝘪𝘴, in which 𝘱𝘦𝘳𝘧𝘰𝘳𝘪𝘯 𝘧𝘰𝘳𝘮𝘴 𝘱𝘰𝘳𝘦𝘴 𝘢𝘯𝘥 𝘨𝘳𝘢𝘯𝘻𝘺𝘮𝘦𝘴 𝘦𝘯𝘵𝘦𝘳 𝘵𝘰 𝘵𝘳𝘪𝘨𝘨𝘦𝘳 𝘢𝘱𝘰𝘱𝘵𝘰𝘴𝘪𝘴. Second, 𝘵𝘩𝘳𝘰𝘶𝘨𝘩 𝘥𝘦𝘢𝘵𝘩 𝘳𝘦𝘤𝘦𝘱𝘵𝘰𝘳 𝘦𝘯𝘨𝘢𝘨𝘦𝘮𝘦𝘯𝘵, such as 𝘍𝘢𝘴𝘓 𝘰𝘳 𝘛𝘙𝘈𝘐𝘓, activating 𝘱𝘳𝘰𝘨𝘳𝘢𝘮𝘮𝘦𝘥 𝘤𝘦𝘭𝘭 𝘥𝘦𝘢𝘵𝘩 from outside [1]. 

𝗠𝗼𝗱𝗮𝗹𝗶𝘁𝗶𝗲𝘀 𝗼𝗳 𝗜𝗺𝗺𝘂𝗻𝗼𝘁𝗵𝗲𝗿𝗮𝗽𝘆 
CD8⁺ cells are the backbone of cell-based cancer immunotherapy. 
𝘊𝘈𝘙-𝘛 𝘤𝘦𝘭𝘭𝘴 are engineered to recognize tumor-associated antigens. 
𝘛𝘊𝘙-𝘛 𝘤𝘦𝘭𝘭𝘴 employ transduced TCRs to target peptide–MHC complexes. 
𝘉𝘪𝘛𝘌𝘴 (𝘣𝘪𝘴𝘱𝘦𝘤𝘪𝘧𝘪𝘤 𝘛 𝘤𝘦𝘭𝘭 𝘦𝘯𝘨𝘢𝘨𝘦𝘳𝘴) redirect endogenous CTLs against tumors. 
𝘛𝘐𝘓/𝘢𝘥𝘰𝘱𝘵𝘪𝘷𝘦 𝘤𝘦𝘭𝘭 𝘵𝘩𝘦𝘳𝘢𝘱𝘺 reinfuses expanded tumor-infiltrating lymphocytes [2–5]. 

𝗚𝗲𝗿𝗺𝗮𝗻 𝗥𝗲𝘀𝗲𝗮𝗿𝗰𝗵  
Prof. Hinrich Abken (Berlin) pioneered the early engineering of CAR-T cells, with a focus on fine-tuning activation thresholds [2]. 
Prof. Wolfgang Uckert (MDC Berlin) advanced TCR gene therapy, designing TCR-T cells with enhanced specificity and persistence [3]. 
Prof. Georg Schett (Erlangen) recently broke ground by using CAR-T cells to induce remission in autoimmune disease, extending their reach beyond oncology [4]. 

𝗦𝗽𝗲𝗰𝘂𝗹𝗮𝘁𝗶𝘃𝗲 𝗛𝘆𝗽𝗼𝘁𝗵𝗲𝘀𝗶𝘀 
Logic-gated T cells mainly control antigen recognition (e.g., AND/OR/NOT gates for tumor targets). Imagine CD8⁺ T cells that only unleash perforin/granzyme when both a tumor antigen AND a hostile cytokine environment are present, but remain silenced if a self-antigen or tissue homeostasis signal is detected. 
This would represent a shift from ´tumor-recognition circuits´ → to ´effector-function circuits,´ potentially allowing therapeutic auto-shutdown in autoimmunity while preserving anti-tumor precision.  

Stay tuned for 𝗗𝗮𝘆 𝟭𝟴: 𝗧𝗿𝗲𝗴𝘀 – 𝗠𝗮𝘀𝘁𝗲𝗿𝘀 𝗼𝗳 𝗦𝘂𝗽𝗽𝗿𝗲𝘀𝘀𝗶𝗼𝗻 𝗮𝗻𝗱 𝗧𝗼𝗹𝗲𝗿𝗮𝗻𝗰𝗲 

𝗥𝗲𝗳𝗲𝗿𝗲𝗻𝗰𝗲𝘀 
1. Janeway’s Immunobiology, 9th Ed. 
2. DOI: 10.1089/hum.2021.165 
3. https://doi.org/10.1182/blood-2012-02-412973 
4. DOI: 10.1016/S0140-6736(23)01126-1 
5. doi: 10.1038/nrclinonc.2011.116 

#100DaysofImmunology #CytotoxicTcells #Immunotherapy #CART #TCRT #BiTEs #TILs #AdoptiveCellTherapy #CancerImmunology #Autoimmunity